ConductScience.org, home

Trial · NCT03231085

Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryVariation from reference in hemoglobin rate at the day before surgeryHemoglobin rate change from reference day (right before treatment) to one day before surgery (from 22 days to 5 weeks maximum)Variation of hemoglobin rate between reference value (collected right before the implementation of treatment) and preoperative hemoglobin rate (collected one day before surgery)
SecondaryVariation from reference in hemoglobin rate at the day before surgery depending on the reference iron statusReference day (right before treatment) and one day before surgery (from 22 days to 5 weeks maximum)
Variation of hemoglobin rate between reference value (collected right before the implementation of treatment) and preoperative hemoglobin rate (collected one day before surgery) depending on the reference iron status
SecondaryVariation from reference in hemoglobin rate at the day before surgery depending on the inflammatory state of patient evaluated by CRP rate before treatmentReference day (right before treatment) and one day before surgery (from 22 days to 5 weeks maximum)
Variation of hemoglobin rate between reference value (collected right before the implementation of treatment) and preoperative hemoglobin rate (collected one day before surgery) depending on the CRP rate before treatment
SecondaryFrequency of EPO treatment discontinuation at the end of 2nd injection15 days before surgeryNumber of patient stopping EPO injections at the end of 2nd injection
SecondaryVariation from reference in iron status at the day before surgeryReference day (right before treatment) and one day before surgery (from 22 days to 5 weeks maximum)Changes in iron status between reference day (right before the implementation of treatment) and preoperative iron status (one day before surgery)
SecondaryOccurrence of adverse events due to experimental treatmentsfrom treatment administration to end of patient follow-upComparision of adverse event du to experimental treatments (ferric carboxymaltose versus ferrous fumarate)
SecondaryCompliance of oral iron treatmentAt the end of oral iron treatmentEvaluated by visual analogic scale (0 the minimum to 10 the maximum)
SecondaryRate of blood transfusion in perioperative phase and during 3 days following surgeryPerioperative phase and during 3 days following surgeryNumber of transfused patients among all patients
SecondaryNumber of packed red blood cells transfused in perioperative phase and during 3 days followingPerioperative phase and during 3 days following surgery
SecondaryVolume of packed red blood cells transfusedPerioperative phase and during 3 days following surgeryVolume in mL/kg
SecondaryTotal perioperative blood lossPerioperative phase and during 3 days following surgeryExpressed in red blood cell mass
SecondaryCost of oral ferrous fumarate treatment compared to ferric carboxymaltose treatmentAt the end of patient folllow-up (6 months after surgery)

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03231085/registered